Table 1

 Clinical characteristics of the study population at baseline

Patient NoSex, age (years)Active organ involvement at time of RTXPrevious treatment failed at time of RTX introductionCYC cumulative (g)Continued treatment at time of RTXBefore/after RTX
cANCAB cellsBVAS 1DEI
*Latest prednisolone dosage before switch to RTX.
E, ear, nose, and throat; Ey, eye; B, constitutional symptoms; L, lung; K, kidney; S, skin; A, arthritis; CYC, cyclophosphamide; PRD, prednisolone; MTX, methotrexate.
1F/54E, Ey, BCYC 20 mg/kg every 3rd week PRD 10 mg od* Infliximab 5 mg/kg/month for 3 mo115CYC 1.2 g every 3rd week IV PRD 25 mg od64/641/06/65/5
2F/33E, EyMTX 20 mg/wk PRD 30 mg od* Infliximab 5 mg/kg/month for 3 mo28MTX 20 mg/wk PRD 30 mg od128/1285/08/104/4
3M/4 YE, EyCYC 100 mg od PRD 10 mg od* Infliximab 5 mg/kg/month for 3 mo63CYC 100 mg od PRD 10 mg od32/327/010/72/2
4M/46E, Ey, BCYC 12 mg/kg every 3rd week PRD 30 mg od* Infliximab 5 mg/kg/month for 3 mo6CYC 12 mg/kg every 3rd week PRD 15 mg od128/12820/07/75/5
5F/51E, Ey, BCYC 100 mg od PRD 10 mg od* Infliximab 5 mg/kg/month for 3 mo129CYC 100 mg od PRD 20 mg od128/1281/09/95/4
6M/27E, L, BCYC 100 mg od PRD 17 mg od* Infliximab 5 mg/kg/month for 3 mo20CYC 100 mg od PRD 15 mg od128/1282/09/05/2
7M/36E, L, K, S, A, BLeflunomide 30 mg od PRD 17 mg od* Etanercept 25 mg twice a wk90MTX 25 mg/wk PRD 20 mg od128/642/06/114/4
8M/38E, L, K, A, BMycophenolate mofetil 2 g od PRD 10 mg od* Etanercept 25 mg twice a wk163Mycophenolate mofetil 2 g od PRD 10 mg od*128/12814/05/02/2